Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer | Zendy

Yu Chen | Zendy; Gang Chen | Zendy; Jin Li | Zendy; Yingying Huang | Zendy; Yi Li | Zendy; Jing Lin | Zendy; Lizhu Chen | Zendy; Jianping Lu | Zendy; Yuqi Wang | Zendy; Changxi Wang | Zendy; Leong Kin Pan | Zendy; Xuefeng Xia | Zendy; Xin Yi | Zendy; Chuanben Chen | Zendy; Xiongwei Zheng | Zendy; Zengqing Guo | Zendy; Jianji Pan | Zendy

Open Access

Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer

Author(s) -

Yu Chen,

Gang Chen,

Jin Li,

Yingying Huang,

Yi Li,

Jing Lin,

Lizhu Chen,

Jianping Lu,

Yuqi Wang,

Changxi Wang,

Leong Kin Pan,

Xuefeng Xia,

Xin Yi,

Chuanben Chen,

Xiongwei Zheng,

Zengqing Guo,

Jianji Pan

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.11895

Subject(s) - lung cancer , oncology , medicine , ataxia telangiectasia , transcriptome , cohort , genome wide association study , cancer , gene , cancer research , biology , genotype , single nucleotide polymorphism , dna damage , genetics , gene expression , dna

This cohort study examines the association of comutation of tumor protein p53 ( TP53 ) and ataxia-telangiectasia mutated ( ATM ) genes with response to immune checkpoint inhibitor (ICI) treatment and overall survival among patients with non–small cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research